Recommendations for the management of hemophagocytic lymphohistiocytosis in adults
Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome
induced by aberrantly activated macrophages and cytotoxic T cells. The primary (genetic) …
induced by aberrantly activated macrophages and cytotoxic T cells. The primary (genetic) …
A consensus review on malignancy‐associated hemophagocytic lymphohistiocytosis in adults
N Daver, K McClain, CE Allen, SA Parikh, Z Otrock… - Cancer, 2017 - Wiley Online Library
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of severe immune activation and
dysregulation resulting in extreme and often life‐threatening inflammation. HLH has been …
dysregulation resulting in extreme and often life‐threatening inflammation. HLH has been …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
MV Maus, S Alexander, MR Bishop… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant
numbers of patients with hematological cancers. While these unique immunotherapies have …
numbers of patients with hematological cancers. While these unique immunotherapies have …
Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry
S Birndt, T Schenk, B Heinevetter… - Journal of cancer …, 2020 - Springer
Purpose Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory
syndrome emerging from a deregulated immune response due to various triggers. In adults …
syndrome emerging from a deregulated immune response due to various triggers. In adults …
[HTML][HTML] Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
V Montesarchio, R Parrella, C Iommelli… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background The inflammatory pathology observed in severe COVID-19 disease caused by
the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is …
the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is …
Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH Steering …
S Ehl, I Astigarraga, T von Bahr Greenwood… - The Journal of Allergy …, 2018 - Elsevier
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory
syndrome requiring aggressive immunosuppressive therapy. Following 2 large international …
syndrome requiring aggressive immunosuppressive therapy. Following 2 large international …
[HTML][HTML] The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response
FI Arnaldez, SJ O'Day, CG Drake, BA Fox… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
The pandemic caused by the novel coronavirus SARS-CoV-2 has placed an unprecedented
burden on healthcare systems around the world. In patients who experience severe disease …
burden on healthcare systems around the world. In patients who experience severe disease …
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
A Titov, A Petukhov, A Staliarova, D Motorin… - Cell death & …, 2018 - nature.com
Currently, immunotherapy is attracting a lot of attention and may potentially become a
leading approach in the treatment of cancer. One emerging therapeutic, the chimeric …
leading approach in the treatment of cancer. One emerging therapeutic, the chimeric …
[HTML][HTML] IL-6 modulation for COVID-19: the right patients at the right time?
PA Ascierto, B Fu, H Wei - Journal for immunotherapy of cancer, 2021 - ncbi.nlm.nih.gov
The ongoing pandemic caused by the novel coronavirus SARS-CoV-2 has disrupted the
global economy and strained healthcare systems to their limits. After the virus first emerged …
global economy and strained healthcare systems to their limits. After the virus first emerged …
Assessing thrombocytopenia in the intensive care unit: the past, present, and future
R Zarychanski, DS Houston - Hematology 2014, the American …, 2017 - ashpublications.org
Thrombocytopenia is common among patients admitted to the intensive care unit (ICU).
Multiple pathophysiological mechanisms may contribute, including thrombin-mediated …
Multiple pathophysiological mechanisms may contribute, including thrombin-mediated …